The global contrast enhanced ultrasound market is anticipated to reach USD 2.99 billion by 2030. It is projected to grow at a CAGR of 5.70% from 2024 - 2030, according to a new report by Grand View Research, Inc. The rising prevalence of chronic disorders such as cardiovascular ailments, cancer, and liver disease, growing geriatric population, and increasing technological advancements in the ultrasound imaging technology are the major factors anticipated to boost the contrast-enhanced ultrasound market growth over the forecast period. Growth in the market is further propelled using contrast-enhanced ultrasound over other imaging modalities like CT and MRI has become more popular due to its lower cost, portability, and lack of ionizing radiation.
The rising prevalence of cardiovascular diseases fueling the market growth. According to the World Health Organization (WHO), an estimated 17.9 million deaths occur each year due to cardiovascular diseases, making it the leading cause of death globally. In 2022, it is expected that there will be an increase in the number of people diagnosed with cardiovascular diseases. This is where contrast-enhanced ultrasound (CEUS) can play a crucial role in helping to detect and monitor these conditions. CEUS uses a contrast agent that enhances the ultrasound image, allowing for better visualization of the heart and blood vessels. It can be used to diagnose conditions such as heart valve disease, aortic aneurysm, and peripheral artery disease.
Furthermore, CEUS is a non-invasive and safe imaging modality that does not use ionizing radiation. This makes it a preferred option over other imaging modalities like CT and MRI, which use ionizing radiation. In 2021, a study published in the Journal of the American College of Cardiology showed that CEUS had high diagnostic accuracy in detecting coronary artery disease compared to other imaging modalities. With its many benefits, CEUS is becoming an increasingly important tool in diagnosing and managing cardiovascular diseases.
Based on product, the equipment segment held the largest revenue share in 2023. This can be attributed to the largest installed base of ultrasound imaging technology compatible with CEUS.
The contrast agents segment is expected to grow at the fastest CAGR of 6.32% during the forecast period owing to its approval of usage in the liver and pediatric imaging by the FDA.
Based on type, the non-targeted segment held the largest revenue share in 2023 as most of the commercially available contrast agents are non-targeted in nature.
The hospitals segment held the largest market share in 2023 owing to the increasing number of emergency visits with medical conditions such as abdominal pain, abdominal/thoracic trauma, and cardiac complications
The clinics segment is anticipated to witness lucrative CAGR over the forecast period owing to the realization of economic and patient care benefits with the adoption of sonography devices in practice among physicians at primary and secondary care
In Asia Pacific, the market is expected to grow at the fastest CAGR owing to the limited accessibility to advanced CT/MRI imaging modalities such as CT and MRI, and the growing burden of cardiovascular disorders in China and India.
Please note The report will be delivered in 2-3 business days upon order notification.
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Type
1.2.3. End-use
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America